Department of Neurology.
Center for Motor Neuron Biology and Disease, and.
JCI Insight. 2023 Sep 22;8(18):e171878. doi: 10.1172/jci.insight.171878.
Spinal muscular atrophy (SMA) is a pediatric-onset neuromuscular disorder caused by insufficient survival motor neuron (SMN) protein. SMN restorative therapies are now approved for the treatment of SMA; however, they are not curative, likely due to a combination of imperfect treatment timing, inadequate SMN augmentation, and failure to optimally target relevant organs. Here, we consider the implications of imperfect treatment administration, focusing specifically on outcomes for skeletal muscle. We examine the evidence that muscle plays a contributing role in driving neuromuscular dysfunction in SMA. Next, we discuss how SMN might regulate the health of myofibers and their progenitors. Finally, we speculate on therapeutic outcomes of failing to raise muscle SMN to healthful levels and present strategies to restore function to this tissue to ensure better treatment results.
脊髓性肌萎缩症(SMA)是一种儿科发病的神经肌肉疾病,由运动神经元存活基因(SMN)蛋白不足引起。目前已有修复 SMN 的治疗方法被批准用于 SMA 的治疗;然而,这些治疗方法并不能治愈疾病,这可能是由于治疗时机不理想、SMN 增强不足以及未能优化针对相关器官的治疗等多种原因所致。在这里,我们考虑了治疗效果不理想的影响,特别是针对骨骼肌的结果。我们研究了肌肉在 SMA 神经肌肉功能障碍中起作用的证据。接下来,我们讨论了 SMN 如何调节肌纤维及其祖细胞的健康。最后,我们推测未能将肌肉 SMN 提高到健康水平的治疗结果,并提出了恢复该组织功能的策略,以确保更好的治疗效果。